Younger highly myopic patients have a higher risk of being steroid responders

Article

Younger patients with high myopia are at more risk of a postoperative steroid response after uneventful cataract surgery, according to an investigation published in the Journal of Cataract and Refractive Surgery.

Younger patients with high myopia are at more risk of a postoperative steroid response after uneventful cataract surgery, according to an investigation published in the Journal of Cataract and Refractive Surgery.

Dr David F. Chang et al., Los Altos, California, USA, conducted a case-control, retrospective chart review on 1642 patients who underwent uneventful cataract surgery. Patients were administered topical prednisolone acetate 1.0% postoperatively.

Ocular axial length (AL), patient age and intraocular pressure (IOP) were preoperatively recorded, 1-day postoperatively and at least once in the initial postoperative month. During this time the patients received a topical corticosteroid agent.

If the patients experienced an increase in IOP of more than 25% while receiving topical prednisolone, and this reduced by more than 25% once treatment had ceased, then they were considered to be steroid responders. The age and AL of those patients who had a steroid response and those who didn't were compared for analysis.

Out of 1642 patients, 39 were diagnosed as steroid responders. It was concluded that younger age and longer AL were linked with high steroid response risk. The results suggest steroid responders may require more IOP monitoring or topical anti-inflammatory medications.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.